Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte Inc.

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte yesterday and set a price target of $11.00. The company’s shares closed yes...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUMA	$1.22	+8.93%	6.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUMA	$1.22	+8.9%	6.04M
3
4
5
6

HUMA

HUMA

No Data Available

Get Humacyte Inc. Data in Excel

Get Humacyte Inc. Data in Excel